1
|
Pamies D, Ekert J, Zurich MG, Frey O, Werner S, Piergiovanni M, Freedman BS, Keong Teo AK, Erfurth H, Reyes DR, Loskill P, Candarlioglu P, Suter-Dick L, Wang S, Hartung T, Coecke S, Stacey GN, Wagegg BA, Dehne EM, Pistollato F, Leist M. Recommendations on fit-for-purpose criteria to establish quality management for microphysiological systems and for monitoring their reproducibility. Stem Cell Reports 2024; 19:604-617. [PMID: 38670111 PMCID: PMC11103889 DOI: 10.1016/j.stemcr.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2023] [Revised: 03/28/2024] [Accepted: 03/28/2024] [Indexed: 04/28/2024] Open
Abstract
Cell culture technology has evolved, moving from single-cell and monolayer methods to 3D models like reaggregates, spheroids, and organoids, improved with bioengineering like microfabrication and bioprinting. These advancements, termed microphysiological systems (MPSs), closely replicate tissue environments and human physiology, enhancing research and biomedical uses. However, MPS complexity introduces standardization challenges, impacting reproducibility and trust. We offer guidelines for quality management and control criteria specific to MPSs, facilitating reliable outcomes without stifling innovation. Our fit-for-purpose recommendations provide actionable advice for achieving consistent MPS performance.
Collapse
Affiliation(s)
- David Pamies
- Department of Biomedical Science, University of Lausanne, Lausanne, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland.
| | - Jason Ekert
- Jason E Ekert: UCB Pharma, Cambridge, MA, USA
| | - Marie-Gabrielle Zurich
- Department of Biomedical Science, University of Lausanne, Lausanne, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | | | - Sophie Werner
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland; University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences, Muttenz, Switzerland; Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | | | - Benjamin S Freedman
- Division of Nephrology, Kidney Research Institute, and Institute for Stem Cell and Regenerative Medicine, Department of Medicine, University of Washington, Seattle, WA 98109, USA; Plurexa LLC, Seattle, WA 98109, USA
| | - Adrian Kee Keong Teo
- Stem Cells and Diabetes Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Proteos, Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Precision Medicine Translational Research Programme (TRP), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | | | - Darwin R Reyes
- National Institute of Standards and Technology, Gaithersburg, MD, USA
| | - Peter Loskill
- NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany; Department for Microphysiological Systems, Institute of Biomedical Engineering, Faculty of Medicine, Eberhard Karls University Tübingen, Tübingen, Germany; 3R Center for In Vitro Models and Alternatives to Animal Testing, Eberhard Karls University Tübingen, Tübingen, Germany
| | | | - Laura Suter-Dick
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland; University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences, Muttenz, Switzerland
| | - Shan Wang
- Department of Biomedical Science, University of Lausanne, Lausanne, Switzerland
| | - Thomas Hartung
- Doerenkamp-Zbinden Professor and Chair for Evidence-based Toxicology, Johns Hopkins Bloomberg School of Public Health and Whiting School of Engineering, Baltimore, MD, USA; CAAT Europe, University of Konstanz, Konstanz, Germany
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Glyn N Stacey
- International Stem Cell Banking Initiative, 2 High Street, Barley, Herts SG88HZ, UK; National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing 100190, China; Institute for Stem Cell and Regenerative Merdicine, Chinese Academy of Sciences, Beijing 100101, China
| | | | | | | | - Marcel Leist
- CAAT Europe, University of Konstanz, Konstanz, Germany; In vitro Toxicology and Biomedicine, Department inaugurated by the Doerenkamp-Zbinden foundation, University of Konstanz, Konstanz, Germany
| |
Collapse
|
2
|
Parvatam S, Pamies D, Pistollato F, Beken S, Mariappan I, Roth A, Piergiovanni M, G C Maisonneuve B, Ewart L, Majumder A, Dandekar P, Date R, Mahadik K, Thiyagarajan S, Coecke S. Taking the leap toward human-specific nonanimal methodologies: The need for harmonizing global policies for microphysiological systems. Stem Cell Reports 2024; 19:37-40. [PMID: 38134927 PMCID: PMC10828677 DOI: 10.1016/j.stemcr.2023.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Revised: 11/20/2023] [Accepted: 11/20/2023] [Indexed: 12/24/2023] Open
Abstract
With a recent amendment, India joined other countries that have removed the legislative barrier toward the use of human-relevant methods in drug development. Here, global stakeholders weigh in on the urgent need to globally harmonize the guidelines toward the standardization of microphysiological systems. We discuss a possible framework for establishing scientific confidence and regulatory approval of these methods.
Collapse
Affiliation(s)
| | - David Pamies
- SCAHT - Swiss Centre for Applied Human Toxicology. University of Basel. Missionsstrasse 64, 4055 Basel, Switzerland
| | | | - Sonja Beken
- Federal Agency for Medicines and Health Products, Brussels, Belgium
| | | | | | | | | | - Lorna Ewart
- Emulate Inc, 27 Drydock Avenue, Boston, MA, USA
| | | | | | | | - Kasturi Mahadik
- Centre for Predictive Human Model Systems, Atal Incubation Centre-Centre for Cellular and Molecular Biology (AIC-CCMB), Hyderabad, India
| | | | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| |
Collapse
|
3
|
Pelkonen O, Abass K, Parra Morte JM, Panzarea M, Testai E, Rudaz S, Louisse J, Gundert-Remy U, Wolterink G, Jean-Lou CM D, Coecke S, Bernasconi C. Metabolites in the regulatory risk assessment of pesticides in the EU. Front Toxicol 2023; 5:1304885. [PMID: 38188093 PMCID: PMC10770266 DOI: 10.3389/ftox.2023.1304885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Accepted: 11/30/2023] [Indexed: 01/09/2024] Open
Abstract
A large majority of chemicals is converted into metabolites through xenobiotic-metabolising enzymes. Metabolites may present a spectrum of characteristics varying from similar to vastly different compared with the parent compound in terms of both toxicokinetics and toxicodynamics. In the pesticide arena, the role of metabolism and metabolites is increasingly recognised as a significant factor particularly for the design and interpretation of mammalian toxicological studies and in the toxicity assessment of pesticide/metabolite-associated issues for hazard characterization and risk assessment purposes, including the role of metabolites as parts in various residues in ecotoxicological adversities. This is of particular relevance to pesticide metabolites that are unique to humans in comparison with metabolites found in in vitro or in vivo animal studies, but also to disproportionate metabolites (quantitative differences) between humans and mammalian species. Presence of unique or disproportionate metabolites may underlie potential toxicological concerns. This review aims to present the current state-of-the-art of comparative metabolism and metabolites in pesticide research for hazard and risk assessment, including One Health perspectives, and future research needs based on the experiences gained at the European Food Safety Authority.
Collapse
Affiliation(s)
- Olavi Pelkonen
- Research Unit of Biomedicine, Pharmacology and Toxicology, University of Oulu, Oulu, Finland
| | - Khaled Abass
- Department of Environmental Health Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
- Sharjah Institute for Medical Research (SIMR), University of Sharjah, Sharjah, United Arab Emirates
- Research Unit of Biomedicine and Internal Medicine, Faculty of Medicine, University of Oulu, Oulu, Finland
| | | | | | - Emanuela Testai
- Mechanisms, Biomarkers and Models Unit, Environment and Health Department, Istituto Superiore di Sanità, Rome, Italy
| | - Serge Rudaz
- School of Pharmaceutical Sciences, University of Geneva, CMU, Geneva, Switzerland
| | - Jochem Louisse
- EFSA, European Food Safety Authority, Parma, Italy
- Wageningen Food Safety Research (WFSR), Wageningen, Netherlands
| | - Ursula Gundert-Remy
- Institute of Clinical Pharmacology and Toxicology, Charité–Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | - Gerrit Wolterink
- Centre for Prevention, Lifestyle and Health, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | | | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | |
Collapse
|
4
|
Naik NN, Vadloori B, Poosala S, Srivastava P, Coecke S, Smith A, Akhtar A, Roper C, Radhakrishnan S, Bhyravbhatla B, Damle M, Pulla VK, Hackethal J, Horland R, Li AP, Pati F, Singh MS, Occhetta P, Bisht R, Dandekar P, Bhagavatula K, Pajkrt D, Johnson M, Weber T, Huang J, Hysenaj L, Mallar B, Ramray B, Dixit S, Joshi S, Kulkarni M. Advances in Animal Models and Cutting-Edge Research in Alternatives: Proceedings of the Third International Conference on 3Rs Research and Progress, Vishakhapatnam, 2022. Altern Lab Anim 2023:2611929231180428. [PMID: 37282515 DOI: 10.1177/02611929231180428] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Animal experimentation has been integral to drug discovery and development and safety assessment for many years, since it provides insights into the mechanisms of drug efficacy and toxicity (e.g. pharmacology, pharmacokinetics and pharmacodynamics). However, due to species differences in physiology, metabolism and sensitivity to drugs, the animal models can often fail to replicate the effects of drugs and chemicals in human patients, workers and consumers. Researchers across the globe are increasingly applying the Three Rs principles by employing innovative methods in research and testing. The Three Rs concept focuses on: the replacement of animal models (e.g. with in vitro and in silico models or human studies), on the reduction of the number of animals required to achieve research objectives, and on the refinement of existing experimental practices (e.g. eliminating distress and enhancing animal wellbeing). For the last two years, Oncoseek Bio-Acasta Health, a 3-D cell culture-based cutting-edge translational biotechnology company, has organised an annual International Conference on 3Rs Research and Progress. This series of global conferences aims to bring together researchers with diverse expertise and interests, and provides a platform where they can share and discuss their research to promote practices according to the Three Rs principles. In November 2022, the 3rd international conference, Advances in Animal Models and Cutting-Edge Research in Alternatives, took place at the GITAM University in Vishakhapatnam (AP, India) in a hybrid format (i.e. online and in-person). These conference proceedings provide details of the presentations, which were categorised under five different topic sessions. It also describes a special interactive session on in silico strategies for preclinical research in oncology, which was held at the end of the first day.
Collapse
Affiliation(s)
| | | | | | - Pratima Srivastava
- Biology Discovery and Services Division, Aragen Life Science, Hyderabad, India
| | - Sandra Coecke
- European Commission Joint Research Centre, Ispra, Italy
| | - Adrian Smith
- Norecopa c/o Norwegian Veterinary Institute, Oslo, Norway
| | - Aysha Akhtar
- Center for Contemporary Sciences, Gaithersburg, MD, USA
| | - Clive Roper
- Roper Toxicology Consulting Limited, Edinburgh, UK
| | | | | | | | | | | | | | | | - Falguni Pati
- Department of Biomedical Engineering, IIT Hyderabad, Hyderabad, India
| | - Manu Smriti Singh
- Department of Biotechnology and Center of Excellence for Nanosensors and Nanomedicines, Bennett University, Noida, India
| | | | - Rohit Bisht
- Department of Science-Regulatory Toxicology, People for the Ethical Treatment of Animals (PETA), Delhi, India
| | - Prajakta Dandekar
- Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, India
| | | | - Dasja Pajkrt
- Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | | | - Tilo Weber
- Animal Welfare Academy of the German Animal Welfare Federation, Neubiberg, Germany
| | - John Huang
- TheWell Bioscience, North Brunswick, NJ, USA
| | | | - Banerjee Mallar
- Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
- BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India
| | - Bhat Ramray
- Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, India
- BioSystems Science and Engineering, Indian Institute of Science, Bangalore, India
| | | | | | | |
Collapse
|
5
|
Carnesecchi E, Langezaal I, Browne P, Batista-Leite S, Campia I, Coecke S, Dagallier B, Deceuninck P, Dorne JLC, Tarazona JV, Le Goff F, Leinala E, Morath S, Munn S, Richardson J, Paini A, Wittwehr C. OECD harmonised template 201: Structuring and reporting mechanistic information to foster the integration of new approach methodologies for hazard and risk assessment of chemicals. Regul Toxicol Pharmacol 2023:105426. [PMID: 37277057 DOI: 10.1016/j.yrtph.2023.105426] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 05/31/2023] [Accepted: 06/02/2023] [Indexed: 06/07/2023]
Abstract
In the European Union, the Chemicals Strategy for Sustainability (CSS) highlights the need to enhance the identification and assessment of substances of concern while reducing animal testing, thus fostering the development and use of New Approach Methodologies (NAMs) such as in silico, in vitro and in chemico. In the United States, the Tox21 strategy aims at shifting toxicological assessments away from traditional animal studies towards target-specific, mechanism-based and biological observations mainly obtained by using NAMs. Many other jurisdictions around the world are also increasing the use of NAMs. Hence, the provision of dedicated non-animal toxicological data and reporting formats as a basis for chemical risk assessment is necessary. Harmonising data reporting is crucial when aiming at re-using and sharing data for chemical risk assessment across jurisdictions. The OECD has developed a series of OECD Harmonised Templates (OHT), which are standard data formats designed for reporting information used for the risk assessment of chemicals relevant to their intrinsic properties, including effects on human health (e.g., toxicokinetics, skin sensitisation, repeated dose toxicity) and the environment (e.g., toxicity to test species and wildlife, biodegradation in soil, metabolism of residues in crops). The objective of this paper is to demonstrate the applicability of the OHT standard format for reporting information under various chemical risk assessment regimes, and to provide users with practical guidance on the use of OHT 201, in particular to report test results on intermediate effects and mechanistic information.
Collapse
Affiliation(s)
- Edoardo Carnesecchi
- Organisation for Economic Co-operation and Development (OECD), Environment Directorate, 75775, Paris CEDEX 16, France.
| | | | - Patience Browne
- Organisation for Economic Co-operation and Development (OECD), Environment Directorate, 75775, Paris CEDEX 16, France
| | | | - Ivana Campia
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Bertrand Dagallier
- Organisation for Economic Co-operation and Development (OECD), Environment Directorate, 75775, Paris CEDEX 16, France
| | | | - Jean Lou Cm Dorne
- European Food Safety Authority (EFSA), Via Carlo Magno, 1A, 43126, Parma, Italy
| | - Jose V Tarazona
- European Food Safety Authority (EFSA), Via Carlo Magno, 1A, 43126, Parma, Italy
| | - Francois Le Goff
- European Chemicals Agency (ECHA), Telakkakatu 6, P.O. Box 400, FI-0012, Helsinki, Finland
| | - Eeva Leinala
- Organisation for Economic Co-operation and Development (OECD), Environment Directorate, 75775, Paris CEDEX 16, France
| | | | - Sharon Munn
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Jane Richardson
- European Food Safety Authority (EFSA), Via Carlo Magno, 1A, 43126, Parma, Italy
| | - Alicia Paini
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | |
Collapse
|
6
|
Magurany KA, Chang X, Clewell R, Coecke S, Haugabrooks E, Marty S. A Pragmatic Framework for the Application of New Approach Methodologies in One Health Toxicological Risk Assessment. Toxicol Sci 2023; 192:kfad012. [PMID: 36782355 PMCID: PMC10109535 DOI: 10.1093/toxsci/kfad012] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
Globally, industries and regulatory authorities are faced with an urgent need to assess the potential adverse effects of chemicals more efficiently by embracing new approach methodologies (NAMs). NAMs include cell and tissue methods (in vitro), structure-based/toxicokinetic models (in silico), methods that assess toxicant interactions with biological macromolecules (in chemico), and alternative models. Increasing knowledge on chemical toxicokinetics (what the body does with chemicals) and toxicodynamics (what the chemicals do with the body) obtained from in silico and in vitro systems continues to provide opportunities for modernizing chemical risk assessments. However, directly leveraging in vitro and in silico data for derivation of human health-based reference values has not received regulatory acceptance due to uncertainties in extrapolating NAM results to human populations, including metabolism, complex biological pathways, multiple exposures, interindividual susceptibility and vulnerable populations. The objective of this article is to provide a standardized pragmatic framework that applies integrated approaches with a focus on quantitative in vitro to in vivo extrapolation (QIVIVE) to extrapolate in vitro cellular exposures to human equivalent doses from which human reference values can be derived. The proposed framework intends to systematically account for the complexities in extrapolation and data interpretation to support sound human health safety decisions in diverse industrial sectors (food systems, cosmetics, industrial chemicals, pharmaceuticals etc.). Case studies of chemical entities, using new and existing data, are presented to demonstrate the utility of the proposed framework while highlighting potential sources of human population bias and uncertainty, and the importance of Good Method and Reporting Practices.
Collapse
Affiliation(s)
| | | | - Rebecca Clewell
- 21st Century Tox Consulting, Chapel Hill, North Carolina 27517, USA
| | - Sandra Coecke
- European Commission Joint Research Centre, Ispra, Italy
| | - Esther Haugabrooks
- Coca-Cola Company (formerly Physicians Committee for Responsible Medicine), Atlanta, Georgia 30313, USA
| | - Sue Marty
- The Dow Chemical Company, Midland, Michigan 48667, USA
| |
Collapse
|
7
|
Holzer AK, Dreser N, Pallocca G, Mangerich A, Stacey G, Dipalo M, Van de Water B, Rovida C, Wirtz PH, Van Vugt B, Panzarella G, Hartung T, Terron A, Mangas I, Herzler M, Marx-Stoelting P, Coecke S, Leist M. Acceptance criteria for new approach methods in toxicology and human health-relevant life science research - part I. ALTEX 2023; 40:706-712. [PMID: 37889190 DOI: 10.14573/altex.2310021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/02/2023] [Indexed: 10/28/2023]
Abstract
Every test procedure, scientific and non-scientific, has inherent uncertainties, even when performed according to a standard operating procedure (SOP). In addition, it is prone to errors, defects, and mistakes introduced by operators, laboratory equipment, or materials used. Adherence to an SOP and comprehensive validation of the test method cannot guarantee that each test run produces data within the acceptable range of variability and with the precision and accuracy determined during the method validation. We illustrate here (part I) why controlling the validity of each test run is an important element of experimental design. The definition and application of acceptance criteria (AC) for the validity of test runs is important for the setup and use of test methods, particularly for the use of new approach methods (NAM) in toxicity testing. AC can be used for decision rules on how to handle data, e.g., to accept the data for further use (AC fulfilled) or to reject the data (AC not fulfilled). The adherence to AC has important requirements and consequences that may seem surprising at first sight: (i) AC depend on a test method's objectives, e.g., on the types/concentrations of chemicals tested, the regulatory context, the desired throughput; (ii) AC are applied and documented at each test run, while validation of a method (including the definition of AC) is only performed once; (iii) if AC are altered, then the set of data produced by a method can change. AC, if missing, are the blind spot of quality assurance: Test results may not be reliable and comparable. The establishment and uses of AC will be further detailed in part II of this series.
Collapse
Affiliation(s)
- Anna-Katharina Holzer
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | - Nadine Dreser
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | | | - Aswin Mangerich
- Nutritional toxicology, University of Postdam, Potsdam, Germany
| | - Glyn Stacey
- International Stem Cell Banking Initiative, Barley, Herts, UK
| | | | - Bob Van de Water
- Division of Drug Discovery & Safety, Leiden University, Leiden, The Netherlands
| | | | - Petra H Wirtz
- Centre for the Advanced Study of Collective Behaviour, University of Konstanz, Konstanz, Germany
- Biological Work and Health Psychology, Department of Psychology, University of Konstanz, Konstanz, Germany
| | | | - Giulia Panzarella
- Università "Magna Græcia" of Catanzaro, Catanzaro, Italy
- Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany
| | - Thomas Hartung
- CAAT-Europe, University of Konstanz, Konstanz, Germany
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
| | | | - Iris Mangas
- EFSA, European Food Safety Authority, Parma, Italy
| | | | | | - Sandra Coecke
- European Commission, Joint Research Centre, Ispra, Italy
| | - Marcel Leist
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
- CAAT-Europe, University of Konstanz, Konstanz, Germany
| |
Collapse
|
8
|
Hogberg HT, Lam A, Ohayon E, Shahbaz MA, Clerbaux LA, Bal-Price A, Coecke S, Concha R, De Bernardi F, Edrosa E, Hargreaves AJ, Kanninen KM, Munoz A, Pistollato F, Saravanan S, Garcia-Reyero N, Wittwehr C, Sachana M. The Adverse Outcome Pathway Framework Applied to Neurological Symptoms of COVID-19. Cells 2022; 11:cells11213411. [PMID: 36359807 PMCID: PMC9658029 DOI: 10.3390/cells11213411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Revised: 10/20/2022] [Accepted: 10/24/2022] [Indexed: 12/15/2022] Open
Abstract
Several reports have shown that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the potential to also be neurotropic. However, the mechanisms by which SARS-CoV-2 induces neurologic injury, including neurological and/or psychological symptoms, remain unclear. In this review, the available knowledge on the neurobiological mechanisms underlying COVID-19 was organized using the AOP framework. Four AOPs leading to neurological adverse outcomes (AO), anosmia, encephalitis, stroke, and seizure, were developed. Biological key events (KEs) identified to induce these AOs included binding to ACE2, blood–brain barrier (BBB) disruption, hypoxia, neuroinflammation, and oxidative stress. The modularity of AOPs allows the construction of AOP networks to visualize core pathways and recognize neuroinflammation and BBB disruption as shared mechanisms. Furthermore, the impact on the neurological AOPs of COVID-19 by modulating and multiscale factors such as age, psychological stress, nutrition, poverty, and food insecurity was discussed. Organizing the existing knowledge along an AOP framework can represent a valuable tool to understand disease mechanisms and identify data gaps and potentially contribute to treatment, and prevention. This AOP-aligned approach also facilitates synergy between experts from different backgrounds, while the fast-evolving and disruptive nature of COVID-19 emphasizes the need for interdisciplinarity and cross-community research.
Collapse
Affiliation(s)
- Helena T. Hogberg
- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27518, USA
- Johns Hopkins University, Baltimore, MD 21205, USA
- Correspondence: (H.T.H.); (M.S.)
| | - Ann Lam
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA 92111, USA
- Physicians Committee for Responsible Medicine, Washington, DC 20016, USA
| | - Elan Ohayon
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA 92111, USA
- Institute for Green & Open Sciences, Toronto, ON M6J 2J4, Canada
| | - Muhammad Ali Shahbaz
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | | | - Anna Bal-Price
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy
| | - Rachel Concha
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA 92111, USA
| | - Francesca De Bernardi
- Division of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, 21100 Varese, Italy
| | - Eizleayne Edrosa
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA 92111, USA
| | - Alan J. Hargreaves
- School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK
| | - Katja M. Kanninen
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Amalia Munoz
- European Commission, Joint Research Centre (JRC), 2440 Geel, Belgium
| | | | - Surat Saravanan
- Centre for Predictive Human Model Systems Atal Incubation Centre-Centre for Cellular and Molecular Biology, Hyderabad 500039, India
| | - Natàlia Garcia-Reyero
- Environmental Laboratory, US Army Engineer Research & Development Center, Vicksburg, MS 39180, USA
| | - Clemens Wittwehr
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy
| | - Magdalini Sachana
- Environment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), 75016 Paris, France
- Correspondence: (H.T.H.); (M.S.)
| |
Collapse
|
9
|
Shahbaz MA, De Bernardi F, Alatalo A, Sachana M, Clerbaux LA, Muñoz A, Parvatam S, Landesmann B, Kanninen KM, Coecke S. Mechanistic Understanding of the Olfactory Neuroepithelium Involvement Leading to Short-Term Anosmia in COVID-19 Using the Adverse Outcome Pathway Framework. Cells 2022; 11:3027. [PMID: 36230989 PMCID: PMC9563945 DOI: 10.3390/cells11193027] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2022] [Revised: 09/09/2022] [Accepted: 09/19/2022] [Indexed: 12/23/2022] Open
Abstract
Loss of the sense of smell (anosmia) has been included as a COVID-19 symptom by the World Health Organization. The majority of patients recover the sense of smell within a few weeks postinfection (short-term anosmia), while others report persistent anosmia. Several studies have investigated the mechanisms leading to anosmia in COVID-19; however, the evidence is scattered, and the mechanisms remain poorly understood. Based on a comprehensive review of the literature, we aim here to evaluate the current knowledge and uncertainties regarding the mechanisms leading to short-term anosmia following SARS-CoV-2 infection. We applied an adverse outcome pathway (AOP) framework, well established in toxicology, to propose a sequence of measurable key events (KEs) leading to short-term anosmia in COVID-19. Those KEs are (1) SARS-CoV-2 Spike proteins binding to ACE-2 expressed by the sustentacular (SUS) cells in the olfactory epithelium (OE); (2) viral entry into SUS cells; (3) viral replication in the SUS cells; (4) SUS cell death; (5) damage to the olfactory sensory neurons and the olfactory epithelium (OE). This AOP-aligned approach allows for the identification of gaps where more research should be conducted and where therapeutic intervention could act. Finally, this AOP gives a frame to explain several disease features and can be linked to specific factors that lead to interindividual differences in response to SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Muhammad Ali Shahbaz
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Francesca De Bernardi
- Division of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, 21100 Varese, Italy
| | - Arto Alatalo
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Magdalini Sachana
- Environment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), 75775 Paris, France
| | | | - Amalia Muñoz
- European Commission, Joint Research Centre (JRC), 2440 Geel, Belgium
| | - Surat Parvatam
- Centre for Predictive Human Model Systems, Atal Incubation Centre-Centre for Cellular and Molecular Biology (AIC-CCMB), Habsiguda, Hyderabad 500039, India
| | | | - Katja M. Kanninen
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, 70211 Kuopio, Finland
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy
| |
Collapse
|
10
|
Clerbaux LA, Fillipovska J, Muñoz A, Petrillo M, Coecke S, Amorim MJ, Grenga L. Mechanisms Leading to Gut Dysbiosis in COVID-19: Current Evidence and Uncertainties Based on Adverse Outcome Pathways. J Clin Med 2022; 11:5400. [PMID: 36143044 PMCID: PMC9505288 DOI: 10.3390/jcm11185400] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2022] [Revised: 08/24/2022] [Accepted: 09/09/2022] [Indexed: 02/06/2023] Open
Abstract
Alteration in gut microbiota has been associated with COVID-19. However, the underlying mechanisms remain poorly understood. Here, we outlined three potential interconnected mechanistic pathways leading to gut dysbiosis as an adverse outcome following SARS-CoV-2 presence in the gastrointestinal tract. Evidence from the literature and current uncertainties are reported for each step of the different pathways. One pathway investigates evidence that intestinal infection by SARS-CoV-2 inducing intestinal inflammation alters the gut microbiota. Another pathway links the binding of viral S protein to angiotensin-converting enzyme 2 (ACE2) to the dysregulation of this receptor, essential in intestinal homeostasis-notably for amino acid metabolism-leading to gut dysbiosis. Additionally, SARS-CoV-2 could induce gut dysbiosis by infecting intestinal bacteria. Assessing current evidence within the Adverse Outcome Pathway framework justifies confidence in the proposed mechanisms to support disease management and permits the identification of inconsistencies and knowledge gaps to orient further research.
Collapse
Affiliation(s)
| | | | - Amalia Muñoz
- European Commission, Joint Research Centre (JRC), 2440 Geel, Belgium
| | | | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy
| | - Maria-Joao Amorim
- Instituto Gulbenkian de Ciência, 2780-156 Oerias, Portugal
- Católica Medical School, Católica Biomedical Research Centre, Universidade Católica Portuguesa, 1649-023 Lisbon, Portugal
| | - Lucia Grenga
- Département Médicaments et Technologies pour la Santé, Commissariat à l’Énergie Atomique et Aux Énergies Alternatives (CEA), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Paris-Saclay, 30200 Bagnols-sur-Cèze, France
| |
Collapse
|
11
|
Clerbaux LA, Albertini MC, Amigó N, Beronius A, Bezemer GFG, Coecke S, Daskalopoulos EP, del Giudice G, Greco D, Grenga L, Mantovani A, Muñoz A, Omeragic E, Parissis N, Petrillo M, Saarimäki LA, Soares H, Sullivan K, Landesmann B. Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. J Clin Med 2022; 11:4464. [PMID: 35956081 PMCID: PMC9369763 DOI: 10.3390/jcm11154464] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 07/05/2022] [Accepted: 07/06/2022] [Indexed: 12/10/2022] Open
Abstract
Addressing factors modulating COVID-19 is crucial since abundant clinical evidence shows that outcomes are markedly heterogeneous between patients. This requires identifying the factors and understanding how they mechanistically influence COVID-19. Here, we describe how eleven selected factors (age, sex, genetic factors, lipid disorders, heart failure, gut dysbiosis, diet, vitamin D deficiency, air pollution and exposure to chemicals) influence COVID-19 by applying the Adverse Outcome Pathway (AOP), which is well-established in regulatory toxicology. This framework aims to model the sequence of events leading to an adverse health outcome. Several linear AOPs depicting pathways from the binding of the virus to ACE2 up to clinical outcomes observed in COVID-19 have been developed and integrated into a network offering a unique overview of the mechanisms underlying the disease. As SARS-CoV-2 infectibility and ACE2 activity are the major starting points and inflammatory response is central in the development of COVID-19, we evaluated how those eleven intrinsic and extrinsic factors modulate those processes impacting clinical outcomes. Applying this AOP-aligned approach enables the identification of current knowledge gaps orientating for further research and allows to propose biomarkers to identify of high-risk patients. This approach also facilitates expertise synergy from different disciplines to address public health issues.
Collapse
Affiliation(s)
- Laure-Alix Clerbaux
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| | | | - Núria Amigó
- Biosfer Teslab SL., 43204 Reus, Spain;
- Department of Basic Medical Sciences, Universitat Rovira i Virgili (URV), 23204 Reus, Spain
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain
| | - Anna Beronius
- Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden;
| | - Gillina F. G. Bezemer
- Impact Station, 1223 JR Hilversum, The Netherlands;
- Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| | - Evangelos P. Daskalopoulos
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| | - Giusy del Giudice
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland; (G.d.G.); (D.G.); (L.A.S.)
| | - Dario Greco
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland; (G.d.G.); (D.G.); (L.A.S.)
| | - Lucia Grenga
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, SPI, F-30200 Bagnols-sur-Ceze, France;
| | - Alberto Mantovani
- Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore di Sanità, 00161 Rome, Italy;
| | - Amalia Muñoz
- European Commission, Joint Research Centre (JRC), 2440 Geel, Belgium;
| | - Elma Omeragic
- Faculty of Pharmacy, University of Sarajevo, 71000 Sarajevo, Bosnia and Herzegovina;
| | - Nikolaos Parissis
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| | - Mauro Petrillo
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| | - Laura A. Saarimäki
- Finnish Hub for Development and Validation of Integrated Approaches (FHAIVE), Faculty of Medicine and Health Technology, Tampere University, 33100 Tampere, Finland; (G.d.G.); (D.G.); (L.A.S.)
| | - Helena Soares
- Laboratory of Immunobiology and Pathogenesis, Chronic Diseases Research Centre, Faculdade de Ciências Médicas Medical School, University of Lisbon, 1649-004 Lisbon, Portugal;
| | - Kristie Sullivan
- Physicians Committee for Responsible Medicine, Washington, DC 20016, USA;
| | - Brigitte Landesmann
- European Commission, Joint Research Centre (JRC), 21027 Ispra, Italy; (S.C.); (E.P.D.); (N.P.); (M.P.); (B.L.)
| |
Collapse
|
12
|
Cassotta M, Bartnicka JJ, Pistollato F, Parvatam S, Weber T, D'Alessandro V, Bastos LF, Coecke S. A worldwide survey on the use of animal‐derived materials and reagents in scientific experimentation. Eng Life Sci 2022; 22:564-583. [PMID: 36093359 PMCID: PMC9444711 DOI: 10.1002/elsc.202100167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 05/25/2022] [Accepted: 06/24/2022] [Indexed: 11/28/2022] Open
Abstract
The use of cell and tissue‐based methods in basic, applied and regulatory science has been increasing exponentially. Animal‐derived components, including serum, coating materials, growth factors and antibodies are routinely used in cell/tissue cultures and in general laboratory practices. In addition to ethical issues, the use and production of animal‐derived materials and reagents raises many scientific concerns, generally associated with presence of undefined components and batch‐to‐batch variability, which may compromise experimental reproducibility. On the other hand, non‐animal materials and reagents, such as human cells, alternatives to animal sera or non‐animal recombinant antibodies, are becoming increasingly available, and their use is encouraged by the EU Directive 2010/63 and the Guidance Document on Good In vitro Method Practices (GIVIMP), published by the Organization for Economic Cooperation and Development (OECD). In an effort to map the current state of use of animal‐derived reagents across different sectors and to identify the obstacles possibly hampering the implementation of non‐animal derived alternatives, a global online survey addressed to scientists working on in vivo, in vitro, in silico methods, in academia as well as pharmaceutical or cosmetic companies, was conducted with the goal to understand: 1) the most commonly used animal‐derived materials and reagents, 2) the main issues associated with the production and use of animal‐derived materials and reagents, 3) the current level of knowledge on available non‐animal alternative materials and reagents, and 4) what educational and information sources could be most useful or impactful to disseminate knowledge on non‐animal alternatives. This paper provides an overview of the survey replies and discusses possible proposals to increase awareness, acceptance and use of non‐animal ingredients.
Collapse
Affiliation(s)
| | | | | | - Surat Parvatam
- Centre for Predictive Human Model Systems Atal Incubation Centre‐Centre for Cellular and Molecular Biology (AIC‐CCMB) Hyderabad India
| | - Tilo Weber
- Department for Alternatives to the Use of Animals in Research, Testing and Education Animal Welfare Academy of the German Animal Welfare Federation Neubiberg Germany
| | | | | | - Sandra Coecke
- European Commission Joint Research Centre (JRC) Ispra Italy
| |
Collapse
|
13
|
Clerbaux LA, Amigó N, Amorim MJ, Bal-Price A, Batista Leite S, Beronius A, Bezemer GFG, Bostroem AC, Carusi A, Coecke S, Concha R, Daskalopoulos EP, De Bernardi F, Edrosa E, Edwards SW, Filipovska J, Garcia-Reyero N, Gavins FNE, Halappanavar S, Hargreaves AJ, Hogberg HT, Huynh MT, Jacobson D, Josephs-Spaulding J, Kim YJ, Kong HJ, Krebs CE, Lam A, Landesmann B, Layton A, Lee YO, Macmillan DS, Mantovani A, Margiotta-Casaluci L, Martens M, Masereeuw R, Mayasich SA, Mei LM, Mortensen H, Munoz Pineiro A, Nymark P, Ohayon E, Ojasi J, Paini A, Parissis N, Parvatam S, Pistollato F, Sachana M, Sørli JB, Sullivan KM, Sund J, Tanabe S, Tsaioun K, Vinken M, Viviani L, Waspe J, Willett C, Wittwehr C. COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease - 3rd CIAO AOP Design Workshop. ALTEX 2022; 39:322–335. [PMID: 35032963 PMCID: PMC10069302 DOI: 10.14573/altex.2112161] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 12/17/2021] [Indexed: 02/07/2023]
Abstract
On April 28-29, 2021, 50 scientists from different fields of expertise met for the 3rd online CIAO workshop. The CIAO project “Modelling the Pathogenesis of COVID-19 using the Adverse Outcome Pathway (AOP) framework” aims at building a holistic assembly of the available scientific knowledge on COVID-19 using the AOP framework. An individual AOP depicts the disease progression from the initial contact with the SARS-CoV-2 virus through biological key events (KE) toward an adverse outcome such as respiratory distress, anosmia or multiorgan failure. Assembling the individual AOPs into a network highlights shared KEs as central biological nodes involved in multiple outcomes observed in COVID-19 patients. During the workshop, the KEs and AOPs established so far by the CIAO members were presented and positioned on a timeline of the disease course. Modulating factors influencing the progression and severity of the disease were also addressed as well as factors beyond purely biological phenomena. CIAO relies on an interdisciplinary crowdsourcing effort, therefore, approaches to expand the CIAO network by widening the crowd and reaching stakeholders were also discussed. To conclude the workshop, it was decided that the AOPs/KEs will be further consolidated, integrating virus variants and long COVID when relevant, while an outreach campaign will be launched to broaden the CIAO scientific crowd.
Collapse
Affiliation(s)
| | | | | | - Anna Bal-Price
- European Commission, Joint Research Centre, Ispra, Italy
| | | | - Anna Beronius
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | - Sandra Coecke
- European Commission, Joint Research Centre, Ispra, Italy
| | - Rachel Concha
- Fairleigh Dickinson University, Green Neuroscience Laboratory, San Diego, CA, USA
| | | | - Francesca De Bernardi
- Division of Otorhinolaryngology, Department of Biotechnologies and Life Sciences, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy
| | - Eizleayne Edrosa
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
| | | | | | | | - Felicity N E Gavins
- The Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK
| | - Sabina Halappanavar
- Environmental Health Science and Research Bureau, Health Canada, Ottawa, Ontario, Canada
| | - Alan J Hargreaves
- School of Science and Technology, Nottingham Trent University, Nottingham, UK
| | - Helena T Hogberg
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Mylène T Huynh
- Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Daniel Jacobson
- Biosciences, Oak Ridge National Laboratory, Oak Ridge, TN, USA
| | | | - Young Jun Kim
- Korea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany
| | - Hyun Joon Kong
- University of Illinois at Urbana-Champaign, Champaign, IL, USA
| | | | - Ann Lam
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
| | | | | | - Yong Oh Lee
- Korea Institute of Science and Technology Europe Forschungsgesellschaft mbH, Saarbrücken, Germany
| | | | | | - Luigi Margiotta-Casaluci
- The Centre for Inflammation Research and Translational Medicine (CIRTM), Brunel University London, London, UK
| | - Marvin Martens
- Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands
| | - Rosalinde Masereeuw
- Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Sally A Mayasich
- University of Wisconsin-Madison Aquatic Sciences Center at US EPA, Duluth, MN, USA
| | | | | | | | - Penny Nymark
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
| | - Elan Ohayon
- Green Neuroscience Laboratory, Neurolinx Research Institute, San Diego, CA, USA
| | - Joshi Ojasi
- Hiranandani College of Pharmacy, Mumbai, India
| | - Alicia Paini
- European Commission, Joint Research Centre, Ispra, Italy
| | | | - Surat Parvatam
- Centre for Predictive Human Model Systems Atal Incubation Centre - Centre for Cellular and Molecular Biology Habsiguda, Hyderabad, India
| | | | - Magdalini Sachana
- Environment Health and Safety Division, Environment Directorate, Organisation for Economic Cooperation and Development (OECD), Paris, France
| | | | | | - Jukka Sund
- European Commission, Joint Research Centre, Ispra, Italy
| | - Shihori Tanabe
- Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki, Japan
| | - Katya Tsaioun
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Mathieu Vinken
- Department of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, Brussels, Belgium
| | | | | | | | | |
Collapse
|
14
|
Pamies D, Leist M, Coecke S, Bowe G, Allen DG, Gstraunthaler G, Bal-Price A, Pistollato F, de Vries RBM, Hogberg HT, Hartung T, Stacey G. Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0). ALTEX 2021; 39:30-70. [PMID: 34882777 DOI: 10.14573/altex.2111011] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 12/09/2021] [Indexed: 06/13/2023]
Abstract
Good Cell and Tissue Culture Practice (GCCP) 2.0 is an updated guidance document from GCCP 1.0 (published by ECVAM in 2005), which was developed for practical use in the laboratory to assure the reproducibility of in vitro (cell-based) work. The update in the guidance was essential as cell models have advanced dramatically to more complex culture systems and need more comprehensive quality management to ensure reproducibility and high-quality scientific data. This document describes six main principles to consider when performing cell culture including characterization and maintenance of essential characteristics, quality management, documentation and reporting, safety, education and training, and ethics. The document does not intend to impose detailed procedures but to describe potential quality issues. It is foreseen that the document will require further updates as the science and technologies evolve over time.
Collapse
Affiliation(s)
- David Pamies
- Department of Biomedical Science, University of Lausanne, Lausanne, Vaud, Switzerland
- Swiss Centre for Applied Human Toxicology (SCAHT), Basel, Switzerland
| | - Marcel Leist
- Center for Alternatives to Animal Testing (CAAT) Europe, University of Konstanz, Konstanz, Germany
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | - Sandra Coecke
- European Commission Joint Research Centre (JRC), Ispra, Italy
| | - Gerard Bowe
- European Commission Joint Research Centre (JRC), Ispra, Italy
| | - David G Allen
- Integrated Laboratory Systems, LLC., Morrisville, NC, USA
| | | | - Anna Bal-Price
- European Commission Joint Research Centre (JRC), Ispra, Italy
| | | | - Rob B M de Vries
- Evidence-based Toxicology Collaboration, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- SYRCLE, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud UMC, Nijmegen, The Netherlands
| | - Helena T Hogberg
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
| | - Thomas Hartung
- Center for Alternatives to Animal Testing (CAAT) Europe, University of Konstanz, Konstanz, Germany
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
| | - Glyn Stacey
- International Stem Cell Banking Initiative, Barley, Herts, UK
- National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing, China
- Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
15
|
Weber A, Birk B, Mueller C, Huener HA, Renko K, Coecke S, Schneider S, Van Ravenzwaay B, Funk-Weyer D, Landsiedel R. Validation and specificity testing of an in vitro method assessing substance-induced DIO1 inhibition in human liver microsomes. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00494-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Pamies D, Leist M, Coecke S, Bowe G, Allen D, Gstraunthaler G, Bal-Price A, Pistollato F, DeVries R, Hartung T, Stacey G. Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) - Draft for stakeholder discussion and call for action. ALTEX 2021; 37:490-492. [PMID: 32686838 DOI: 10.14573/altex.2007091] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 07/10/2020] [Indexed: 11/23/2022]
Affiliation(s)
- David Pamies
- Department of Biomedical Science, University of Lausanne, Lausanne, Vaud, Switzerland
| | - Marcel Leist
- Center for Alternatives to Animal Testing (CAAT) Europe, University of Konstanz, Konstanz, Germany.,In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Gerard Bowe
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Dave Allen
- Integrated Laboratory Systems, LLC., Morrisville, NC, USA
| | | | - Anna Bal-Price
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | | - Rob DeVries
- Evidence-based Toxicology Collaboration, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.,SYRCLE, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud UMC, Nijmegen, The Netherlands
| | - Thomas Hartung
- Center for Alternatives to Animal Testing (CAAT) Europe, University of Konstanz, Konstanz, Germany.,Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
| | - Glyn Stacey
- International Stem Cell Banking Initiative, Barley, Herts, UK.,National Stem Cell Resource Centre, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.,Innovation Academy for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
17
|
Blaauboer BJ, Boobis AR, Castell JV, Coecke S, Groothuis GM, Guillouzo A, Hall TJ, Hawksworth GM, Lorenzon G, Miltenburger HG, Rogiers V, Skett P, Villa P, Wiebel FJ. The Practical Applicability of Hepatocyte Cultures in Routine Testing. Altern Lab Anim 2020. [DOI: 10.1177/026119299402200404] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Bas J. Blaauboer
- Unidad de Hepatologia Experimental, Hospital Universitario La Fe, Avda de Campanar 21, 46009 Valencia, Spain
| | - Alan R. Boobis
- Department of Genetic and In Vitro Toxicology, Janssen Pharmaceutica N.V., Turnhoutsebaan 30, 2340 Beerse, Belgium
| | - Jose V. Castell
- Groningen Institute for Drug Studies, Department of Pharmacokinetics and Drug Delivery, University of Groningen, Antonius Deusinglaan 2, 9713 AW Groningen, The Netherlands
| | - Sandra Coecke
- INSERM U49, Unité de Recherche Hepatologique, Hôpital de Pontchaillou, 35033 Rennes, France
| | - Geny M.M. Groothuis
- MD Laboratories, BP30, 68870 Bartenheim, France; ‘“Department of Medicine and Therapeutics and Department of Biomedical Sciences, Polwarth Building, University of Aberdeen, Aberdeen AB9 2ZD, UK
| | - Andre Guillouzo
- Laboratoire de Toxicologic Génétique et Cellulaire, Département Toxicologic, Roussel UCLAF, 102 route de Noisy, 93235 Romainville Cedex, France
| | - Tony J. Hall
- Cell Biology Laboratory, Institute of Zoology, Technical University, 64287 Darmstadt, Germany
| | - Gabrielle M. Hawksworth
- Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
| | - Giocondo Lorenzon
- Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, UK
| | - Herbert G. Miltenburger
- CNR Center of Cytopharmacology, Department of Pharmacology, University of Milan, via Vanvitelli 32, 20129 Milan, Italy
| | - Vera Rogiers
- Institut für Toxikologie, GSF Forschungszentrum für Umwelt und Gesundheit, D-85758 Neuherberg, Germany
| | - Paul Skett
- Department of Pharmacology, University of Glasgow, Glasgow G12 8QQ, UK
| | - Pia Villa
- CNR Center of Cytopharmacology, Department of Pharmacology, University of Milan, via Vanvitelli 32, 20129 Milan, Italy
| | - Friedrich J. Wiebel
- Institut für Toxikologie, GSF Forschungszentrum für Umwelt und Gesundheit, D-85758 Neuherberg, Germany
| |
Collapse
|
18
|
Krebs A, Waldmann T, Wilks MF, Van Vugt-Lussenburg BMA, Van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, Pallocca G, Luijten M, Leite SB, Kustermann S, Kamp H, Hoeng J, Hewitt P, Herzler M, Hengstler JG, Heinonen T, Hartung T, Hardy B, Gantner F, Fritsche E, Fant K, Ezendam J, Exner T, Dunkern T, Dietrich DR, Coecke S, Busquet F, Braeuning A, Bondarenko O, Bennekou SH, Beilmann M, Leist M. Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data. ALTEX 2020; 36:682-699. [PMID: 31658359 DOI: 10.14573/altex.1909271] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/27/2019] [Accepted: 09/30/2019] [Indexed: 11/23/2022]
Abstract
Only few cell-based test methods are described by Organisation for Economic Co-operation and Development (OECD) test guidelines or other regulatory references (e.g., the European Pharmacopoeia). The majority of toxicity tests still falls into the category of non-guideline methods. Data from these tests may nevertheless be used to support regulatory decisions or to guide strategies to assess compounds (e.g., drugs, agrochemicals) during research and development if they fulfill basic requirements concerning their relevance, reproducibility and predictivity. Only a method description of sufficient clarity and detail allows interpretation and use of the data. To guide regulators faced with increasing amounts of data from non-guideline studies, the OECD formulated Guidance Document 211 (GD211) on method documentation for the purpose of safety assessment. As GD211 is targeted mainly at regulators, it leaves scientists less familiar with regulation uncertain as to what level of detail is required and how individual questions should be answered. Moreover, little attention was given to the description of the test system (i.e., cell culture) and the steps leading to it being established in the guidance. To address these issues, an annotated toxicity test method template (ToxTemp) was developed (i) to fulfill all requirements of GD211, (ii) to guide the user concerning the types of answers and detail of information required, (iii) to include acceptance criteria for test elements, and (iv) to define the cells sufficiently and transparently. The fully annotated ToxTemp is provided here, together with reference to a database containing exemplary descriptions of more than 20 cell-based tests.
Collapse
Affiliation(s)
- Alice Krebs
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Konstanz, Germany
| | - Tanja Waldmann
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | - Martin F Wilks
- Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland
| | | | | | | | - Thomas Steger-Hartmann
- Investigational Toxicology, Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal, Germany
| | - Joelle Ruegg
- Department of Organismal Biology, Uppsala University, Uppsala, Sweden
| | | | - Emma Pedersen
- RISE Research Institutes of Sweden, Göteborg, Sweden
| | - Giorgia Pallocca
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,CAAT-Europe, University of Konstanz, Konstanz, Germany
| | - Mirjam Luijten
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Sofia B Leite
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Stefan Kustermann
- F. Hoffmann - La Roche, Pharma Research and Early Development, Pharmaceutical Sciences - Roche Innovation Center, Basel, Switzerland
| | - Hennicke Kamp
- Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany
| | - Julia Hoeng
- Philip Morris International R&D, Neuchâtel, Switzerland
| | | | - Matthias Herzler
- German Federal Institute for Risk Assessment, Dept. Chemical Safety, Berlin, Germany
| | - Jan G Hengstler
- Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, Dortmund, Germany
| | - Tuula Heinonen
- FICAM, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland
| | - Thomas Hartung
- CAAT-Europe, University of Konstanz, Konstanz, Germany.,Johns Hopkins University, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
| | - Barry Hardy
- Edelweiss Connect GmbH, Technology Park Basel, Basel, Switzerland
| | - Florian Gantner
- Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Ellen Fritsche
- IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
| | - Kristina Fant
- RISE Research Institutes of Sweden, Göteborg, Sweden
| | - Janine Ezendam
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Thomas Exner
- Edelweiss Connect GmbH, Technology Park Basel, Basel, Switzerland
| | | | - Daniel R Dietrich
- Human and Environmental Toxicology, University of Konstanz, Konstanz, Germany
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Francois Busquet
- CAAT-Europe, University of Konstanz, Konstanz, Germany.,ALTERTOX SPRL, Ixelles, Bruxelles, Belgium
| | - Albert Braeuning
- German Federal Institute for Risk Assessment, Dept. Food Safety, Berlin, Germany
| | - Olesja Bondarenko
- Laboratory of Environmental Toxicology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia
| | - Susanne H Bennekou
- The National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - Mario Beilmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Nonclinical Drug Safety, Biberach, Germany
| | - Marcel Leist
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Konstanz, Germany.,CAAT-Europe, University of Konstanz, Konstanz, Germany
| |
Collapse
|
19
|
Louisse J, Alewijn M, Peijnenburg AA, Cnubben NH, Heringa MB, Coecke S, Punt A. Towards harmonization of test methods for in vitro hepatic clearance studies. Toxicol In Vitro 2020; 63:104722. [DOI: 10.1016/j.tiv.2019.104722] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 11/07/2019] [Accepted: 11/13/2019] [Indexed: 12/26/2022]
|
20
|
Krebs A, Waldmann T, Wilks MF, Van Vugt-Lussenburg BMA, Van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, Pallocca G, Luijten M, Leite SB, Kustermann S, Kamp H, Hoeng J, Hewitt P, Herzler M, Hengstler JG, Heinonen T, Hartung T, Hardy B, Gantner F, Fritsche E, Fant K, Ezendam J, Exner T, Dunkern T, Dietrich DR, Coecke S, Busquet F, Braeuning A, Bondarenko O, Bennekou SH, Beilmann M, Leist M. Erratum to Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data. ALTEX 2020; 37:164. [PMID: 31960940 DOI: 10.14573/altex.1909271e] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
In this manuscript, which appeared in ALTEX (2019), 36(4), 682- 699, doi:10.14573/altex.1909271 , the affiliation of Hennicke Kamp should be Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany. Further, the reference to an article by Bal-Price et al. (2015) should have the following doi:10.1007/s00204-015-1464-2 .
Collapse
Affiliation(s)
- Alice Krebs
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Konstanz, Germany
| | - Tanja Waldmann
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany
| | - Martin F Wilks
- Swiss Centre for Applied Human Toxicology, University of Basel, Basel, Switzerland
| | | | | | | | - Thomas Steger-Hartmann
- Investigational Toxicology, Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal, Germany
| | - Joelle Ruegg
- Department of Organismal Biology, Uppsala University, Uppsala, Sweden
| | | | - Emma Pedersen
- RISE Research Institutes of Sweden, Göteborg, Sweden
| | - Giorgia Pallocca
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,CAAT-Europe, University of Konstanz, Konstanz, Germany
| | - Mirjam Luijten
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Sofia B Leite
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Stefan Kustermann
- F. Hoffmann - La Roche, Pharma Research and Early Development, Pharmaceutical Sciences - Roche Innovation Center, Basel, Switzerland
| | - Hennicke Kamp
- Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany
| | - Julia Hoeng
- Philip Morris International R&D, Neuchâtel, Switzerland
| | | | - Matthias Herzler
- German Federal Institute for Risk Assessment, Dept. Chemical Safety, Berlin, Germany
| | - Jan G Hengstler
- Leibniz Research Centre for Working Environment and Human Factors (IfADo), Technical University of Dortmund, Dortmund, Germany
| | - Tuula Heinonen
- FICAM, Faculty of Medicine and Life Sciences, Tampere University, Tampere, Finland
| | - Thomas Hartung
- CAAT-Europe, University of Konstanz, Konstanz, Germany.,Johns Hopkins University, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
| | - Barry Hardy
- Edelweiss Connect GmbH, Technology Park Basel, Basel, Switzerland
| | - Florian Gantner
- Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Ellen Fritsche
- IUF - Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany
| | - Kristina Fant
- RISE Research Institutes of Sweden, Göteborg, Sweden
| | - Janine Ezendam
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Thomas Exner
- Edelweiss Connect GmbH, Technology Park Basel, Basel, Switzerland
| | | | - Daniel R Dietrich
- Human and Environmental Toxicology, University of Konstanz, Konstanz, Germany
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Francois Busquet
- CAAT-Europe, University of Konstanz, Konstanz, Germany.,ALTERTOX SPRL, Ixelles, Bruxelles, Belgium
| | - Albert Braeuning
- German Federal Institute for Risk Assessment, Dept. Food Safety, Berlin, Germany
| | - Olesja Bondarenko
- Laboratory of Environmental Toxicology, National Institute of Chemical Physics and Biophysics, Tallinn, Estonia
| | - Susanne H Bennekou
- The National Food Institute, Technical University of Denmark, Kgs. Lyngby, Denmark
| | - Mario Beilmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Nonclinical Drug Safety, Biberach, Germany
| | - Marcel Leist
- In vitro Toxicology and Biomedicine, Dept inaugurated by the Doerenkamp-Zbinden Foundation, University of Konstanz, Konstanz, Germany.,Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Konstanz, Germany.,CAAT-Europe, University of Konstanz, Konstanz, Germany
| |
Collapse
|
21
|
Bernasconi C, Pelkonen O, Andersson TB, Strickland J, Wilk-Zasadna I, Asturiol D, Cole T, Liska R, Worth A, Müller-Vieira U, Richert L, Chesne C, Coecke S. Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study. Toxicol In Vitro 2019; 60:212-228. [PMID: 31158489 PMCID: PMC6718736 DOI: 10.1016/j.tiv.2019.05.019] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2019] [Accepted: 05/29/2019] [Indexed: 12/12/2022]
Abstract
CYP enzyme induction is a sensitive biomarker for phenotypic metabolic competence of in vitro test systems; it is a key event associated with thyroid disruption, and a biomarker for toxicologically relevant nuclear receptor-mediated pathways. This paper summarises the results of a multi-laboratory validation study of two in vitro methods that assess the potential of chemicals to induce cytochrome P450 (CYP) enzyme activity, in particular CYP1A2, CYP2B6, and CYP3A4. The methods are based on the use of cryopreserved primary human hepatocytes (PHH) and human HepaRG cells. The validation study was coordinated by the European Union Reference Laboratory for Alternatives to Animal Testing of the European Commission's Joint Research Centre and involved a ring trial among six laboratories. The reproducibility was assessed within and between laboratories using a validation set of 13 selected chemicals (known human inducers and non-inducers) tested under blind conditions. The ability of the two methods to predict human CYP induction potential was assessed. Chemical space analysis confirmed that the selected chemicals are broadly representative of a diverse range of chemicals. The two methods were found to be reliable and relevant in vitro tools for the assessment of human CYP induction, with the HepaRG method being better suited for routine testing. Recommendations for the practical application of the two methods are proposed.
Collapse
Affiliation(s)
| | - Olavi Pelkonen
- Research Unit of Biomedicine/Pharmacology and Toxicology, Faculty of Medicine, Aapistie 5B, University of Oulu, FIN-90014, Finland; Clinical Research Center, Oulu University Hospital, Finland
| | - Tommy B Andersson
- Drug Metabolism and Pharmacokinetics, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden; Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, SE-171 77 Stockholm, Sweden
| | - Judy Strickland
- Integrated Laboratory Systems (contractor supporting NICEATM), Research Triangle Park, North, Carolina, 27709, USA
| | | | - David Asturiol
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Thomas Cole
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Roman Liska
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Andrew Worth
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Ursula Müller-Vieira
- Boehringer Ingelheim, Germany. Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, an der Riss, Germany
| | - Lysiane Richert
- KaLy-Cell, 20A, rue du Général Leclerc, 67115 Plobsheim, France(g) Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France
| | - Christophe Chesne
- Biopredic International, Parc d'activité de la Bretèche Bâtiment A4, 35760 Saint Grégoire, France
| | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy.
| |
Collapse
|
22
|
Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Roi AJ, Prieto P, Sabbioni E, Worth A, Zuang V. ECVAM's Response to the Changing Political Environment for Alternatives: Consequences of the European Union Chemicals and Cosmetics Policies. Altern Lab Anim 2019; 31:473-81. [PMID: 15598174 DOI: 10.1177/026119290303100504] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The European Centre for the Validation of Alternative Methods (ECVAM) has restructured its services by directly targeting the animal tests that need to be replaced. In view of the short time-lines for making available and implementing validated methods, ECVAM is offering to steer the process by bringing together the inputs of stakeholders and encouraging the early involvement of regulators. In essence, steering groups formed by ECVAM senior staff, and complemented with external experts, will carry out the project management and will coordinate the various inputs.
Collapse
Affiliation(s)
- Thomas Hartung
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra (VA), Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Rispin A, Harbell JW, Klausner M, Jordan FT, Coecke S, Gupta K, Stitzel K. Quality Assurance for In Vitro Alternative Test Methods: Quality Control Issues in Test Kit Production. Altern Lab Anim 2019; 32 Suppl 1B:725-9. [DOI: 10.1177/026119290403201s120] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
In vitro toxicology methods are being adopted by regulatory agencies worldwide. Many of these methods have been validated by using proprietary materials, often in the form of test kits. Guidelines for the use of Good Laboratory Practice methods for in vitro methods have been proposed. However, users of the data from these methods also need to be reassured that the proprietary materials and the test kits will provide consistent, good quality data over time, not just during the validation process. This paper presents an overview of the methods currently used by representatives of kit manufacturers and contract testing laboratories to ensure that the results from methods that utilise test kits are reproducible over time and across different types of test materials. This information will be valuable as a basis for future discussion on the need for formalised oversight of the quality of these materials.
Collapse
Affiliation(s)
- Amy Rispin
- US Environmental Protection Agency, Office of Pesticide Programs (7506C), Washington, DC, USA
| | - John W. Harbell
- Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA
| | | | | | - Sandra Coecke
- European Centre for the Validation of Alternative Methods, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy
| | - Kailash Gupta
- US Consumer Product Safety Commission, Bethesda, MD, USA
| | | |
Collapse
|
24
|
Prieto P, Blaauboer BJ, de Boer AG, Boveri M, Cecchelli R, Clemedson C, Coecke S, Forsby A, Galla HJ, Garberg P, Greenwood J, Price A, Tähti H. Blood-Brain Barrier In Vitro Models and Their Application in Toxicology: The Report and Recommendations of ECVAM Workshop 49,. Altern Lab Anim 2019; 32:37-50. [PMID: 15603552 DOI: 10.1177/026119290403200107] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Pilar Prieto
- ECVAM, Institute for Health & Consumer Protection, European Commission Joint Research Centre, 21020 Ispra (VA), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Hartung T, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Hoffmann S, Roi AJ, Prieto P, Sabbioni E, Scott L, Worth A, Zuang V. A Modular Approach to the ECVAM Principles on Test Validity. Altern Lab Anim 2019; 32:467-72. [PMID: 15656771 DOI: 10.1177/026119290403200503] [Citation(s) in RCA: 173] [Impact Index Per Article: 34.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The European Centre for the Validation of Alternative Methods (ECVAM) proposes to make the validation process more flexible, while maintaining its high standards. The various aspects of validation are broken down into independent modules, and the information necessary to complete each module is defined. The data required to assess test validity in an independent peer review, not the process, are thus emphasised. Once the information to satisfy all the modules is complete, the test can enter the peer-review process. In this way, the between-laboratory variability and predictive capacity of a test can be assessed independently. Thinking in terms of validity principles will broaden the applicability of the validation process to a variety of tests and procedures, including the generation of new tests, new technologies (for example, genomics, proteomics), computer-based models (for example, quantitative structure-activity relationship models), and expert systems. This proposal also aims to take into account existing information, defining this as retrospective validation, in contrast to a prospective validation study, which has been the predominant approach to date. This will permit the assessment of test validity by completing the missing information via the relevant validation procedure: prospective validation, retrospective validation, catch-up validation, or a combination of these procedures.
Collapse
Affiliation(s)
- Thomas Hartung
- ECVAM, Institute for Health & Consumer Protection, European Commission Joint Research Centre, 21020 Ispra (VA), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea JF, Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat JA, Worth A. Metabolism: A Bottleneck in In Vitro Toxicological Test Development. Altern Lab Anim 2019; 34:49-84. [PMID: 16522150 DOI: 10.1177/026119290603400113] [Citation(s) in RCA: 104] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Sandra Coecke
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Oredsson S, Coecke S, van der Valk J, Vinken M. What is understood by "animal-free research"? Toxicol In Vitro 2019; 57:143-144. [PMID: 30849472 DOI: 10.1016/j.tiv.2019.03.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2018] [Revised: 02/28/2019] [Accepted: 03/01/2019] [Indexed: 10/27/2022]
Affiliation(s)
| | - Sandra Coecke
- European Commission, Joint Research Centre, Ispra, Italy
| | - Jan van der Valk
- 3Rs-Centre Utrecht Life Sciences, Utrecht University, Utrecht, the Netherlands
| | - Mathieu Vinken
- European Society of Toxicology In Vitro, the Netherlands; Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|
28
|
Clerbaux LA, Coecke S, Lumen A, Kliment T, Worth AP, Paini A. Capturing the applicability of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research. Sci Total Environ 2018; 645:97-108. [PMID: 30015123 PMCID: PMC6162338 DOI: 10.1016/j.scitotenv.2018.07.122] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 07/09/2018] [Accepted: 07/10/2018] [Indexed: 06/01/2023]
Abstract
Costs, scientific and ethical concerns related to animal tests for regulatory decision-making have stimulated the development of alternative methods. When applying alternative approaches, kinetics have been identified as a key element to consider. Membrane transporters affect the kinetic processes of absorption, distribution, metabolism and excretion (ADME) of various compounds, such as drugs or environmental chemicals. Therefore, pharmaceutical scientists have intensively studied transporters impacting drug efficacy and safety. Besides pharmacokinetics, transporters are considered as major determinant of toxicokinetics, potentially representing an essential piece of information in chemical risk assessment. To capture the applicability of transporter data for kinetic-based risk assessment in non-pharmaceutical sectors, the EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) created a survey with a view of identifying the improvements needed when using in vitro and in silico methods. Seventy-three participants, from different sectors and with various kinds of expertise, completed the survey. The results revealed that transporters are investigated mainly during drug development, but also for risk assessment purposes of food and feed contaminants, industrial chemicals, cosmetics, nanomaterials and in the context of environmental toxicology, by applying both in vitro and in silico tools. However, to rely only on alternative methods for chemical risk assessment, it is critical that the data generated by in vitro and in silico methods are scientific integer, reproducible and of high quality so that they are trusted by decision makers and used by industry. In line, the respondents identified various challenges related to the interpretation and use of transporter data from non-animal methods. Overall, it was determined that a combined mechanistically-anchored in vitro-in silico approach, validated against available human data, would gain confidence in using transporter data within an animal-free risk assessment paradigm. Finally, respondents involved primarily in fundamental research expressed lower confidence in non-animal studies to unravel complex transporter mechanisms.
Collapse
Affiliation(s)
- Laure-Alix Clerbaux
- European Commission, Joint Research Centre, Via E. Fermi 2749, 21027 Ispra, Italy.
| | - Sandra Coecke
- European Commission, Joint Research Centre, Via E. Fermi 2749, 21027 Ispra, Italy
| | - Annie Lumen
- National Center for Toxicological Research, US Food and Drug Administration (FDA), Jefferson, AR, USA
| | | | - Andrew P Worth
- European Commission, Joint Research Centre, Via E. Fermi 2749, 21027 Ispra, Italy
| | - Alicia Paini
- European Commission, Joint Research Centre, Via E. Fermi 2749, 21027 Ispra, Italy
| |
Collapse
|
29
|
Gouliarmou V, Lostia AM, Coecke S, Bernasconi C, Bessems J, Dorne JL, Ferguson S, Testai E, Remy UG, Brian Houston J, Monshouwer M, Nong A, Pelkonen O, Morath S, Wetmore BA, Worth A, Zanelli U, Zorzoli MC, Whelan M. Establishing a systematic framework to characterise in vitro methods for human hepatic metabolic clearance. Toxicol In Vitro 2018; 53:233-244. [DOI: 10.1016/j.tiv.2018.08.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 07/17/2018] [Accepted: 08/08/2018] [Indexed: 12/26/2022]
|
30
|
Coecke S, Bowe G, Browne P. Microphysiological human stem cell systems for toxicity testing. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.1117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
31
|
Hoffmann W, Gradinaru J, Farcal L, Caul-Futy M, Huang S, Wiszniewski L, Parissis N, Morath S, Fortaner S, Cole T, Reginato E, Carrupt PA, Constant S, Coecke S. Establishment of a Human 3D Tissue-Based Assay for Upper Respiratory Tract Absorption. ACTA ACUST UNITED AC 2018. [DOI: 10.1089/aivt.2017.0035] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Wiebke Hoffmann
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
- University of Vienna, Institute of Nutritional and Physiological Chemistry, Vienna, Austria
| | - Julieta Gradinaru
- Pharmacochemistry Unit, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Lucian Farcal
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
- Douglas Connect GmbH, Basel, Switzerland
| | | | | | | | - Nikolaos Parissis
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| | - Siegfried Morath
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| | - Salvador Fortaner
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| | - Thomas Cole
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| | - Emilie Reginato
- Pharmacochemistry Unit, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | - Pierre-Alain Carrupt
- Pharmacochemistry Unit, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland
| | | | - Sandra Coecke
- European Commission Joint Research Centre, The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| |
Collapse
|
32
|
Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O. Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics. Basic Clin Pharmacol Toxicol 2018. [DOI: 10.1111/bcpt.13004] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Jukka Hakkola
- Research Unit of Biomedicine, Pharmacology and Toxicology; Faculty of Medicine; University of Oulu; Oulu Finland
- Medical Research Center Oulu; University of Oulu; Oulu Finland
| | | | - Sandra Coecke
- European Commission Joint Research Centre; EURL ECVAM; Ispra Italy
| | | | - Tommy B. Andersson
- Drug Metabolism and Pharmacokinetics; Cardiovascular and Metabolic Diseases; IMED Biotech Unit; AstraZeneca; Gothenburg Sweden
- Department of Physiology and Pharmacology; Section of Pharmacogenetics; Karolinska Institutet; Stockholm Sweden
| | - Olavi Pelkonen
- Research Unit of Biomedicine, Pharmacology and Toxicology; Faculty of Medicine; University of Oulu; Oulu Finland
- Medical Research Center Oulu; University of Oulu; Oulu Finland
| |
Collapse
|
33
|
Pamies D, Bal-Price A, Chesné C, Coecke S, Dinnyes A, Eskes C, Grillari R, Gstraunthaler G, Hartung T, Jennings P, Leist M, Martin U, Passier R, Schwamborn JC, Stacey GN, Ellinger-Ziegelbauer H, Daneshian M. Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems. ALTEX 2018; 35:353-378. [PMID: 29697851 DOI: 10.14573/altex.1710081] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2018] [Accepted: 04/11/2018] [Indexed: 11/23/2022]
Abstract
A major reason for the current reproducibility crisis in the life sciences is the poor implementation of quality control measures and reporting standards. Improvement is needed, especially regarding increasingly complex in vitro methods. Good Cell Culture Practice (GCCP) was an effort from 1996 to 2005 to develop such minimum quality standards also applicable in academia. This paper summarizes recent key developments in in vitro cell culture and addresses the issues resulting for GCCP, e.g. the development of induced pluripotent stem cells (iPSCs) and gene-edited cells. It further deals with human stem-cell-derived models and bioengineering of organo-typic cell cultures, including organoids, organ-on-chip and human-on-chip approaches. Commercial vendors and cell banks have made human primary cells more widely available over the last decade, increasing their use, but also requiring specific guidance as to GCCP. The characterization of cell culture systems including high-content imaging and high-throughput measurement technologies increasingly combined with more complex cell and tissue cultures represent a further challenge for GCCP. The increasing use of gene editing techniques to generate and modify in vitro culture models also requires discussion of its impact on GCCP. International (often varying) legislations and market forces originating from the commercialization of cell and tissue products and technologies are further impacting on the need for the use of GCCP. This report summarizes the recommendations of the second of two workshops, held in Germany in December 2015, aiming map the challenge and organize the process or developing a revised GCCP 2.0.
Collapse
Affiliation(s)
- David Pamies
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, MD, USA
| | - Anna Bal-Price
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | | | - Sandra Coecke
- European Commission, Joint Research Centre (JRC), Ispra, Italy
| | - Andras Dinnyes
- Biotalentum Ltd, Godollo, Hungary.,Molecular Animal Biotechnology Laboratory, Szent Istvan University, Godollo, Hungary
| | - Chantra Eskes
- Services & Consultations on Alternative Methods (SeCAM), Magliaso, Switzerland
| | - Regina Grillari
- University of Natural Resources and Life Sciences Vienna, Austria.,Evercyte GmbH, Vienna, Austria
| | | | - Thomas Hartung
- Center for Alternatives to Animal Testing (CAAT), Johns Hopkins University, Baltimore, MD, USA.,CAAT-Europe, University of Konstanz, Konstanz, Germany
| | - Paul Jennings
- Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, The Netherlands
| | - Marcel Leist
- CAAT-Europe, University of Konstanz, Konstanz, Germany
| | - Ulrich Martin
- Leibniz Research Laboratories for Biotechnology and Artificial Organs, Department of Cardiothoracic, Transplantation and Vascular Surgery, REBIRTH - Cluster of Excellence, Hannover Medical School, Hannover, Germany
| | - Robert Passier
- Department of Applied Stem Cell Technologies, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.,Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands
| | - Jens C Schwamborn
- Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg
| | - Glyn N Stacey
- National Institute for Biological Standardization and Control, a center of the Medicines and Health-care Regulatory Agency, South Mimms, Hertfordshire, UK
| | | | | |
Collapse
|
34
|
Eskes C, Boström AC, Bowe G, Coecke S, Hartung T, Hendriks G, Pamies D, Piton A, Rovida C. Good cell culture practices & in vitro toxicology. Toxicol In Vitro 2017; 45:272-277. [DOI: 10.1016/j.tiv.2017.04.022] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Revised: 04/04/2017] [Accepted: 04/06/2017] [Indexed: 11/30/2022]
|
35
|
Whelan M, Worth A, Coecke S, Blaauboer B. Dedication to Dr J.M. Zaldívar Comenges (1958–2012). Toxicol In Vitro 2017. [PMCID: PMC5754319 DOI: 10.1016/j.tiv.2017.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
36
|
|
37
|
Lostia A, Whelan M, Coecke S, Gouliarmou V, Zorzoli M, Mendoza E, Fortaner S. Standardisation of in vitro human hepatic metabolic clearance methods. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.1352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Pamies D, Bal-Price A, Simeonov A, Tagle D, Allen D, Gerhold D, Yin D, Pistollato F, Inutsuka T, Sullivan K, Stacey G, Salem H, Leist M, Daneshian M, Vemuri MC, McFarland R, Coecke S, Fitzpatrick SC, Lakshmipathy U, Mack A, Wang WB, Yamazaki D, Sekino Y, Kanda Y, Smirnova L, Hartung T. Good Cell Culture Practice for stem cells and stem-cell-derived models. ALTEX 2016; 34:95-132. [PMID: 27554434 DOI: 10.14573/altex.1607121] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/12/2016] [Accepted: 08/23/2016] [Indexed: 11/23/2022]
Abstract
The first guidance on Good Cell Culture Practice (GCCP) dates back to 2005. This document expands this to include aspects of quality assurance for in vitro cell culture focusing on the increasingly diverse cell types and culture formats used in research, product development, testing and manufacture of biotechnology products and cell-based medicines. It provides a set of basic principles of best practice that can be used in training new personnel, reviewing and improving local procedures, and helping to assure standard practices and conditions for the comparison of data between laboratories and experimentation performed at different times. This includes recommendations for the documentation and reporting of culture conditions. It is intended as guidance to facilitate the generation of reliable data from cell culture systems, and is not intended to conflict with local or higher level legislation or regulatory requirements. It may not be possible to meet all recommendations in this guidance for practical, legal or other reasons. However, when it is necessary to divert from the principles of GCCP, the risk of decreasing the quality of work and the safety of laboratory staff should be addressed and any conclusions or alternative approaches justified. This workshop report is considered a first step toward a revised GCCP 2.0.
Collapse
Affiliation(s)
- David Pamies
- Center for Alternative to Animal Testing, Johns Hopkins University, Baltimore, MD, USA
| | - Anna Bal-Price
- European Commission, Joint Research Centre, Ispra, VA, Italy
| | - Anton Simeonov
- National Center for Advancing Translational Sciences - National Institutes of Health, Rockville, MD, USA
| | - Danilo Tagle
- National Center for Advancing Translational Sciences - National Institutes of Health, Rockville, MD, USA
| | - Dave Allen
- Contractor supporting the NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), Morrisville, NC, USA
| | - David Gerhold
- National Center for Advancing Translational Sciences - National Institutes of Health, Rockville, MD, USA
| | - Dezhong Yin
- ATCC Cell Systems American Type Culture Collection, Gaithersburg, MD, USA
| | | | - Takashi Inutsuka
- Pharmacological Evaluation Institute of Japan (PEIJ), Tokyo, Japan
| | - Kristie Sullivan
- Physicians Committee for Responsible Medicine, Washington, DC, USA
| | - Glyn Stacey
- National Institute for Biological Standardization and Control, South Mimms, Hertfordshire, UK
| | - Harry Salem
- US Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD, USA
| | - Marcel Leist
- Center for Alternatives to Animal Testing-Europe, University of Konstanz, Konstanz, Germany
| | - Mardas Daneshian
- Center for Alternatives to Animal Testing-Europe, University of Konstanz, Konstanz, Germany
| | - Mohan C Vemuri
- Life Sciences Solutions, Thermo Fisher Scientific, Carlsbad, CA, USA
| | - Richard McFarland
- Center for Food Safety and Applied Nutrition/FDA, College Park, MD, USA
| | - Sandra Coecke
- European Commission, Joint Research Centre, Ispra, VA, Italy
| | | | - Uma Lakshmipathy
- Life Sciences Solutions, Thermo Fisher Scientific, Carlsbad, CA, USA
| | - Amanda Mack
- Cellular Dynamics International, Madison, WI, USA
| | - Wen Bo Wang
- Cellular Dynamics International, Madison, WI, USA
| | - Daiju Yamazaki
- Division of Pharmacology, National Institute of Health Sciences, Tokyo, Japan
| | - Yuko Sekino
- Division of Pharmacology, National Institute of Health Sciences, Tokyo, Japan
| | - Yasunari Kanda
- Division of Pharmacology, National Institute of Health Sciences, Tokyo, Japan
| | - Lena Smirnova
- Center for Alternative to Animal Testing, Johns Hopkins University, Baltimore, MD, USA
| | - Thomas Hartung
- Center for Alternative to Animal Testing, Johns Hopkins University, Baltimore, MD, USA.,Center for Alternatives to Animal Testing-Europe, University of Konstanz, Konstanz, Germany
| |
Collapse
|
39
|
Griesinger C, Desprez B, Coecke S, Casey W, Zuang V. Validation of Alternative In Vitro Methods to Animal Testing: Concepts, Challenges, Processes and Tools. Adv Exp Med Biol 2016; 856:65-132. [PMID: 27671720 DOI: 10.1007/978-3-319-33826-2_4] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
This chapter explores the concepts, processes, tools and challenges relating to the validation of alternative methods for toxicity and safety testing. In general terms, validation is the process of assessing the appropriateness and usefulness of a tool for its intended purpose. Validation is routinely used in various contexts in science, technology, the manufacturing and services sectors. It serves to assess the fitness-for-purpose of devices, systems, software up to entire methodologies. In the area of toxicity testing, validation plays an indispensable role: "alternative approaches" are increasingly replacing animal models as predictive tools and it needs to be demonstrated that these novel methods are fit for purpose. Alternative approaches include in vitro test methods, non-testing approaches such as predictive computer models up to entire testing and assessment strategies composed of method suites, data sources and decision-aiding tools. Data generated with alternative approaches are ultimately used for decision-making on public health and the protection of the environment. It is therefore essential that the underlying methods and methodologies are thoroughly characterised, assessed and transparently documented through validation studies involving impartial actors. Importantly, validation serves as a filter to ensure that only test methods able to produce data that help to address legislative requirements (e.g. EU's REACH legislation) are accepted as official testing tools and, owing to the globalisation of markets, recognised on international level (e.g. through inclusion in OECD test guidelines). Since validation creates a credible and transparent evidence base on test methods, it provides a quality stamp, supporting companies developing and marketing alternative methods and creating considerable business opportunities. Validation of alternative methods is conducted through scientific studies assessing two key hypotheses, reliability and relevance of the test method for a given purpose. Relevance encapsulates the scientific basis of the test method, its capacity to predict adverse effects in the "target system" (i.e. human health or the environment) as well as its applicability for the intended purpose. In this chapter we focus on the validation of non-animal in vitro alternative testing methods and review the concepts, challenges, processes and tools fundamental to the validation of in vitro methods intended for hazard testing of chemicals. We explore major challenges and peculiarities of validation in this area. Based on the notion that validation per se is a scientific endeavour that needs to adhere to key scientific principles, namely objectivity and appropriate choice of methodology, we examine basic aspects of study design and management, and provide illustrations of statistical approaches to describe predictive performance of validated test methods as well as their reliability.
Collapse
Affiliation(s)
| | | | - Sandra Coecke
- European Commission, Joint Research Centre (JRC),, Ispra, Italy
| | - Warren Casey
- Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.,Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM), Washington, DC, USA
| | - Valérie Zuang
- European Commission, Joint Research Centre (JRC),, Ispra, Italy.
| |
Collapse
|
40
|
Farcal L, Busquet F, Coecke S, Hristescu I, Chesné C, Pellevoisin C, Orasanu A, Diaconeasa Z, Oros A, Pintea A, Socaciu C. Finding opportunities in the area of Alternative Methods to Animal Testing for Romania and inauguration of the Romanian Center for Alternative Test Methods (ROCAM). ALTEX 2015; 32:392-3. [PMID: 26536294 DOI: 10.14573/altex.1509281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Lucian Farcal
- BIOTOX Srl, Cluj-Napoca, Romania.,Douglas Connect GmbH, Zeiningen, Switzerland
| | - Francois Busquet
- Center for Alternatives to Animal Testing, CAAT-Europe, University of Konstanz, Germany
| | - Sandra Coecke
- DG JRC-Institute for Health and Consumer Protection, European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM), Ispra, Italy
| | - Ioana Hristescu
- National Sanitary Veterinary and Food Safety Authority, Bucharest, Romania
| | | | | | - Adriana Orasanu
- Institute for Diagnosis and Animal Health, Bucharest, Romania
| | - Zorita Diaconeasa
- University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania
| | - Adrian Oros
- University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania
| | - Adela Pintea
- University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania
| | - Carmen Socaciu
- University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania
| |
Collapse
|
41
|
Constant S, Hoffmann W, Gradinaru J, Farcal L, Wiszniewski L, Huang S, Carrupt PA, Coecke S. Development of a human airway tissue-based assay for respiratory absorption giving input parameters for PBTK modelling. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Suter-Dick L, Alves PM, Blaauboer BJ, Bremm KD, Brito C, Coecke S, Flick B, Fowler P, Hescheler J, Ingelman-Sundberg M, Jennings P, Kelm JM, Manou I, Mistry P, Moretto A, Roth A, Stedman D, van de Water B, Beilmann M. Stem cell-derived systems in toxicology assessment. Stem Cells Dev 2015; 24:1284-96. [PMID: 25675366 DOI: 10.1089/scd.2014.0540] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Industrial sectors perform toxicological assessments of their potential products to ensure human safety and to fulfill regulatory requirements. These assessments often involve animal testing, but ethical, cost, and time concerns, together with a ban on it in specific sectors, make appropriate in vitro systems indispensable in toxicology. In this study, we summarize the outcome of an EPAA (European Partnership of Alternatives to Animal Testing)-organized workshop on the use of stem cell-derived (SCD) systems in toxicology, with a focus on industrial applications. SCD systems, in particular, induced pluripotent stem cell-derived, provide physiological cell culture systems of easy access and amenable to a variety of assays. They also present the opportunity to apply the vast repository of existing nonclinical data for the understanding of in vitro to in vivo translation. SCD systems from several toxicologically relevant tissues exist; they generally recapitulate many aspects of physiology and respond to toxicological and pharmacological interventions. However, focused research is necessary to accelerate implementation of SCD systems in an industrial setting and subsequent use of such systems by regulatory authorities. Research is required into the phenotypic characterization of the systems, since methods and protocols for generating terminally differentiated SCD cells are still lacking. Organotypical 3D culture systems in bioreactors and microscale tissue engineering technologies should be fostered, as they promote and maintain differentiation and support coculture systems. They need further development and validation for their successful implementation in toxicity testing in industry. Analytical measures also need to be implemented to enable compound exposure and metabolism measurements for in vitro to in vivo extrapolation. The future of SCD toxicological tests will combine advanced cell culture technologies and biokinetic measurements to support regulatory and research applications. However, scientific and technical hurdles must be overcome before SCD in vitro methods undergo appropriate validation and become accepted in the regulatory arena.
Collapse
Affiliation(s)
- Laura Suter-Dick
- 1University of Applied Sciences Northwestern Switzerland, School of Life Sciences, Muttenz, Switzerland
| | - Paula M Alves
- 2iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.,3Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal
| | - Bas J Blaauboer
- 4Division of Toxicology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, the Netherlands
| | - Klaus-Dieter Bremm
- 5Bayer Pharma AG, Global Drug Discovery-Global Early Development, Wuppertal, Germany
| | - Catarina Brito
- 2iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.,3Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal
| | - Sandra Coecke
- 6European Commission Joint Research Centre, Institute for Health and Consumer Protection, EURL ECVAM, Ispra, Italy
| | - Burkhard Flick
- 7BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany
| | | | - Jürgen Hescheler
- 9Institut for Neurophysiology, University of Cologne, Cologne, Germany
| | | | - Paul Jennings
- 11Division of Physiology, Department of Physiology and Medical Physics, Innsbruck Medical University, Innsbruck, Austria
| | | | - Irene Manou
- 13European Partnership for Alternative Approaches to Animal Testing (EPAA), B-Brussels, Belgium
| | - Pratibha Mistry
- 14Syngenta Ltd., Product Safety, Jealott's Hill International Research Station, Berkshire, United Kingdom
| | - Angelo Moretto
- 15Dipartimento di Scienze Biochimiche e Cliniche, Università degli Studi di Milano, Milano, Italy.,16Centro Internazionale per gli Antiparassitari e la Prevenzione Sanitaria, Luigi Sacco Hospital, Milano, Italy
| | - Adrian Roth
- 17F. Hoffmann-La Roche Ltd., Innovation Center Basel, Pharmaceutical Sciences, Basel, Switzerland
| | - Donald Stedman
- 18Pfizer Worldwide Research and Development, Cambridge, Massachusetts
| | - Bob van de Water
- 19Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
| | | |
Collapse
|
43
|
Abstract
Isolated primary hepatocytes are considered as the reference system for in vitro hepatic methods. Following the isolation of primary hepatocytes from liver tissue, an unfavorable process named dedifferentiation is initiated leading to the attenuation of the hepatocellular phenotype both at the morphological and functional level. Freshly isolated hepatocytes can be used immediately or can be cryopreserved for future purposes. Currently, a number of antidedifferentiation strategies exist to extend the life span of isolated hepatocytes. The addition of differentiation-promoting compounds to the hepatocyte culture medium is the oldest and simplest antidedifferentiation approach applied. In the present chapter, the most commonly used medium additives for cultivation and cryopreservation of primary hepatocytes are reviewed.
Collapse
Affiliation(s)
- Varvara Gouliarmou
- EURL ECVAM, Systems Toxicology Unit, Institute for Health and Consumer Protection, European Commission, Joint Research Center, Via Fermi 2749, Ispra, 21027, Italy
| | | | | |
Collapse
|
44
|
Cooper-Hannan R, Harbell JW, Coecke S, Balls M, Bowe G, Cervinka M, Clothier R, Hermann F, Klahm LK, de Lange J, Liebsch M, Vanparys P. The principles of good laboratory practice: application to in vitro toxicology studies. Altern Lab Anim 2014; 27:539-77. [PMID: 25487864 DOI: 10.1177/026119299902700410] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- R Cooper-Hannan
- Qualitas, Danworth Lane, Hurstpierpoint, West Sussex BN6 9LN, UK
| | - J W Harbell
- Institute for In Vitro Science, 21 Firstfield Road, Suite 220, Gaithersburg, MD 20878, USA
| | - S Coecke
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra, Italy
| | - M Balls
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra, Italy
| | - G Bowe
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra, Italy
| | - M Cervinka
- Charles University Faculty of Medicine, Simkova 870, Hradec Králové, Czech Republic
| | - R Clothier
- FRAME Alternatives Laboratory, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH, UK
| | - F Hermann
- RCC Cytotest Cell Research, In den Leppsteinwiessen 19, 64380 Rossdorf, Germany
| | - L K Klahm
- Human and Environmental Safety Division, The Procter and Gamble Company, Cincinnati, OH, USA
| | - J de Lange
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra, Italy
| | - M Liebsch
- ZEBET, BgVV, Diedersdorfer Weg 1, 12277 Berlin, Germany
| | - P Vanparys
- Genetic and In Vitro Toxicology, Janssen Pharmaceutica, Turnhoutse Weg 30, 2340 Beerse, Belgium
| |
Collapse
|
45
|
Coecke S, Rogiers V, Bayliss M, Castell J, Doehmer J, Fabre G, Fry J, Kern A, Westmoreland C. The Use of Long-term Hepatocyte Cultures for Detecting Induction of Drug Metabolising Enzymes: The Current Status. Altern Lab Anim 2014; 27:579-638. [PMID: 25487865 DOI: 10.1177/026119299902700408] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
In this report, metabolically competent in vitro systems have been reviewed, in the context of drug metabolising enzyme induction. Based on the experience of the scientists involved, a thorough survey of the literature on metabolically competent long-term culture models was performed. Following this, a prevalidation proposal for the use of the collagen gel sandwich hepatocyte culture system for drug metabolising enzyme induction was designed, focusing on the induction of the cytochrome P450 enzymes as the principal enzymes of interest. The ultimate goal of this prevalidation proposal is to provide industry and academia with a metabolically competent in vitro alternative for long-term studies. In an initial phase, the prevalidation study will be limited to the investigation of induction. However, proposals for other long-term applications of these systems should be forwarded to the European Centre for the Validation of Alternative Methods for consideration. The prevalidation proposal deals with several issues, including: a) species; b) practical prevalidation methodology; c) enzyme inducers; and d) advantages of working with independent expert laboratories. Since it is preferable to include other alternative tests for drug metabolising enzyme induction, when such tests arise, it is recommended that they meet the same level of development as for the collagen gel sandwich long-term hepatocyte system. Those tests which do so should begin the prevalidation and validation process.
Collapse
Affiliation(s)
- S Coecke
- ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21020 Ispra, Italy
| | - V Rogiers
- Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
| | - M Bayliss
- GlaxoWellcome Research and Development, Park Road, Ware, Hertfordshire SG12 ODP, UK
| | - J Castell
- Unidad de Hepatologia Experimental, Hospital Universitario La Fe, Avda de Campanar 21, 46009 Valencia, Spain
| | - J Doehmer
- Institut für Toxikologie und Umwelthygiene, Technische Universität München, Lazarettstrasse 62, 80636 Munich, Germany
| | - G Fabre
- Preclinical Metabolism and Pharmacokinetics, Sanofi Recherche, 34184 Montpellier, France
| | - J Fry
- School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, Nottingham NG7 2UH
| | - A Kern
- Drug Metabolism and Isotope Chemistry, Bayer, Aprather Weg 18a, 42096 Wuppertal, Germany
| | - C Westmoreland
- GlaxoWellcome Research and Development, Park Road, Ware, Hertfordshire SG12 ODP, UK
| |
Collapse
|
46
|
Wilk-Zasadna I, Bernasconi C, Pelkonen O, Coecke S. Biotransformation in vitro: An essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. Toxicology 2014; 332:8-19. [PMID: 25456264 DOI: 10.1016/j.tox.2014.10.006] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2014] [Revised: 06/11/2014] [Accepted: 10/11/2014] [Indexed: 12/14/2022]
Abstract
Early consideration of the multiplicity of factors that govern the biological fate of foreign compounds in living systems is a necessary prerequisite for the quantitative in vitro-in vivo extrapolation (QIVIVE) of toxicity data. Substantial technological advances in in vitro methodologies have facilitated the study of in vitro metabolism and the further use of such data for in vivo prediction. However, extrapolation to in vivo with a comfortable degree of confidence, requires continuous progress in the field to address challenges such as e.g., in vitro evaluation of chemical-chemical interactions, accounting for individual variability but also analytical challenges for ensuring sensitive measurement technologies. This paper discusses the current status of in vitro metabolism studies for QIVIVE extrapolation, serving today's hazard and risk assessment needs. A short overview of the methodologies for in vitro metabolism studies is given. Furthermore, recommendations for priority research and other activities are provided to ensure further widespread uptake of in vitro metabolism methods in 21st century toxicology. The need for more streamlined and explicitly described integrated approaches to reflect the physiology and the related dynamic and kinetic processes of the human body is highlighted i.e., using in vitro data in combination with in silico approaches.
Collapse
Affiliation(s)
- Iwona Wilk-Zasadna
- Systems Toxicology Unit/EURL ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Varese I-21027, Italy
| | - Camilla Bernasconi
- Systems Toxicology Unit/EURL ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Varese I-21027, Italy
| | - Olavi Pelkonen
- Department of Pharmacology and Toxicology, Institute of Biomedicine, University of Oulu, Oulu, Finland
| | - Sandra Coecke
- Systems Toxicology Unit/EURL ECVAM, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Varese I-21027, Italy.
| |
Collapse
|
47
|
Bal-Price AK, Coecke S, Costa L, Crofton KM, Fritsche E, Goldberg A, Grandjean P, Lein PJ, Li A, Lucchini R, Mundy WR, Padilla S, Persico AM, Seiler AEM, Kreysa J. Advancing the science of developmental neurotoxicity (DNT): testing for better safety evaluation. ALTEX 2013; 29:202-15. [PMID: 22892558 DOI: 10.14573/altex.2012.2.202] [Citation(s) in RCA: 89] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Anna K Bal-Price
- Validation of Alternative Methods Unit, Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra (VA), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Rodrigues RM, Bouhifd M, Bories G, Sacco MG, Gribaldo L, Fabbri M, Coecke S, Whelan MP. Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol In Vitro 2012; 27:760-7. [PMID: 23261643 DOI: 10.1016/j.tiv.2012.12.004] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2012] [Revised: 11/15/2012] [Accepted: 12/07/2012] [Indexed: 11/17/2022]
Abstract
When in vitro test systems are evaluated for assessment of the toxicity of chemical compounds, particular efforts are made to mimic the in vivo reality as close as possible. Cellular models with appropriate metabolic competence, i.e. with the potency to biotransform chemical compounds, are considered crucial since some metabolites have a different toxicity than their parent compounds. In this study a cell based in vitro test system is proposed to investigate the basal cytotoxicity of several reference chemicals. Both metabolic competent HepaRG cells and cells with no or low hepatic enzyme activity (undifferentiated HepaRG and proliferating HepG2) were used. The classic Neutral Red Uptake (NRU) assay proved to be robust and reliable to be applied as viability assay. The test was performed on a robotic platform, which enabled fully automated and simultaneous screening of the compounds. The outcome of these tests grouped the tested compounds in three categories following their detoxification effect (benzo(a)pyrene, valproic acid), their bio-activation effect (aflatoxin B1) and their specific effect on inhibition of cell proliferation (cycloheximide, sodium lauryl sulphate, atropine sulphate monohydrate, acetylsalicylic acid).
Collapse
Affiliation(s)
- Robim M Rodrigues
- Institute for Health and Consumer Protection, European Commission Joint Research Centre, 21027 Ispra (VA), Italy.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Coecke S, Callaerts A, Phillips IR, Vercruysse A, Shephard EA, Rogiers V. Effect of Thyroid Hormones onFlavin-containing Monooxygenase Activity in Co-cultured Adult Rat Hepatocytes. Toxicol In Vitro 2012; 12:335-41. [PMID: 20654415 DOI: 10.1016/s0887-2333(98)80003-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/02/1998] [Indexed: 10/18/2022]
Abstract
The regulation of flavin-containing monooxygenase (FMO) by thyroid hormones was examined under well defined in vitro conditions using adult male rat hepatocytes co-cultured with rat liver epithelial cells of primitive biliary origin. Serum free medium was used to avoid interferences from foetal bovine serum. The effect of thyroxine (T4) and its major metabolite l-triiodothyronine (T3) on FMO activity was estimated spectrophotometrically by measuring the rate of methimazole oxygenation. The highest non-cytotoxic doses of T3 and T4 that could be used in co-cultures were determined by measuring both lactate dehydrogenase leakage into the medium and microsomal protein content of the hepatocytes as a function of culture time. In addition, hormonal responsiveness of the in vitro system used was confirmed by malic enzyme activity measurements. Administration of 10 mum T3 or T4 was found to cause a significant decrease in FMO activity and content, suggesting a suppressive role of both hormones on the regulation of FMO activity in male rats.
Collapse
Affiliation(s)
- S Coecke
- Department of Toxicology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
| | | | | | | | | | | |
Collapse
|
50
|
Leite SB, Wilk-Zasadna I, Zaldivar JM, Airola E, Reis-Fernandes MA, Mennecozzi M, Guguen-Guillouzo C, Chesne C, Guillou C, Alves PM, Coecke S. Three-Dimensional HepaRG Model As An Attractive Tool for Toxicity Testing. Toxicol Sci 2012; 130:106-16. [DOI: 10.1093/toxsci/kfs232] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|